Deutsche Bank
NBIX icon

Deutsche Bank’s Neurocrine Biosciences NBIX Stock Holding History

Deutsche Bank’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-200
Closed -$4K – 5681
2014
Q4 		$4K Buy
+200
New +$3.79K ﹤0.01% 5923

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Deutsche Bank's NBIX Position: Q2 2026 in Review

Deutsche Bank reduced its Neurocrine Biosciences (NBIX) stake by 8.4% in Q2 2026, selling an estimated $4.55M and leaving 334,650 shares worth $56.4M. The position accounts for 0.02% of the portfolio, ranked #632.

Deutsche Bank first reported a position in NBIX in Q2 2013 and has held it in 53 quarters since. The position peaked at $114M in Q3 2018. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Deutsche Bank held 334,650 shares of Neurocrine Biosciences worth $56.4M as of Q2 2026.
  • Deutsche Bank sold 30,695 Neurocrine Biosciences shares in Q2 2026, an estimated $4.55M.
  • Neurocrine Biosciences made up 0.02% of Deutsche Bank's portfolio in Q2 2026, its #632 holding.
  • Deutsche Bank first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 53 quarters since.
  • Deutsche Bank's Neurocrine Biosciences position peaked at $114M in Q3 2018.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.